Having trouble accessing articles? Reset your cache.

Tapentadol ER: Phase III data

In a double-blind, international Phase III trial in 1,030 patients, 100-250 mg twice-daily tapentadol ER significantly reduced average pain intensity from baseline to week 12 of the maintenance period vs. placebo,

Read the full 314 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE